HEADER OXIDOREDUCTASE 17-DEC-01 1KMS TITLE HUMAN DIHYDROFOLATE REDUCTASE COMPLEXED WITH NADPH AND 6-([5- TITLE 2 QUINOLYLAMINO]METHYL)-2,4-DIAMINO-5-METHYLPYRIDO[2,3-D]PYRIMIDINE TITLE 3 (SRI-9439), A LIPOPHILIC ANTIFOLATE COMPND MOL_ID: 1; COMPND 2 MOLECULE: DIHYDROFOLATE REDUCTASE; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: DHFR; COMPND 5 EC: 1.5.1.3; COMPND 6 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3); SOURCE 6 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 8 EXPRESSION_SYSTEM_CELLULAR_LOCATION: CYTOPLASM; SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_VECTOR: PET11A; SOURCE 11 EXPRESSION_SYSTEM_PLASMID: PDFR KEYWDS OXIDOREDUCTASE, ANTIPARASITIC DRUGS, REDUCTASE, LIPOPHILIC KEYWDS 2 ANTIFOLATES EXPDTA X-RAY DIFFRACTION AUTHOR A.E.KLON,A.HEROUX,L.J.ROSS,V.PATHAK,C.A.JOHNSON,J.R.PIPER,D.W.BORHANI REVDAT 5 03-APR-24 1KMS 1 REMARK REVDAT 4 14-FEB-24 1KMS 1 REMARK REVDAT 3 24-FEB-09 1KMS 1 VERSN REVDAT 2 01-APR-03 1KMS 1 JRNL REVDAT 1 10-JUL-02 1KMS 0 JRNL AUTH A.E.KLON,A.HEROUX,L.J.ROSS,V.PATHAK,C.A.JOHNSON,J.R.PIPER, JRNL AUTH 2 D.W.BORHANI JRNL TITL ATOMIC STRUCTURES OF HUMAN DIHYDROFOLATE REDUCTASE COMPLEXED JRNL TITL 2 WITH NADPH AND TWO LIPOPHILIC ANTIFOLATES AT 1.09 A AND 1.05 JRNL TITL 3 A RESOLUTION. JRNL REF J.MOL.BIOL. V. 320 677 2002 JRNL REFN ISSN 0022-2836 JRNL PMID 12096917 JRNL DOI 10.1016/S0022-2836(02)00469-2 REMARK 2 REMARK 2 RESOLUTION. 1.09 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : SHELXL-97 REMARK 3 AUTHORS : G.M.SHELDRICK REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.09 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 20.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.6 REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : 5% OF THE REFLECTIONS WERE REMARK 3 RANDOMLY SELECTED FOR THE REMARK 3 TEST SET. REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (NO CUTOFF). REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : NULL REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.131 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.173 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 3988 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 79411 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL FOR DATA WITH F>4SIG(F). REMARK 3 R VALUE (WORKING + TEST SET, F>4SIG(F)) : NULL REMARK 3 R VALUE (WORKING SET, F>4SIG(F)) : 0.123 REMARK 3 FREE R VALUE (F>4SIG(F)) : 0.162 REMARK 3 FREE R VALUE TEST SET SIZE (%, F>4SIG(F)) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT (F>4SIG(F)) : 3143 REMARK 3 TOTAL NUMBER OF REFLECTIONS (F>4SIG(F)) : 62954 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1484 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 83 REMARK 3 SOLVENT ATOMS : 399 REMARK 3 REMARK 3 MODEL REFINEMENT. REMARK 3 OCCUPANCY SUM OF NON-HYDROGEN ATOMS : 1927.2 REMARK 3 OCCUPANCY SUM OF HYDROGEN ATOMS : 1406.1 REMARK 3 NUMBER OF DISCRETELY DISORDERED RESIDUES : 66 REMARK 3 NUMBER OF LEAST-SQUARES PARAMETERS : 18984 REMARK 3 NUMBER OF RESTRAINTS : 23468 REMARK 3 REMARK 3 RMS DEVIATIONS FROM RESTRAINT TARGET VALUES. REMARK 3 BOND LENGTHS (A) : 0.013 REMARK 3 ANGLE DISTANCES (A) : 0.032 REMARK 3 SIMILAR DISTANCES (NO TARGET VALUES) (A) : 0.000 REMARK 3 DISTANCES FROM RESTRAINT PLANES (A) : 0.029 REMARK 3 ZERO CHIRAL VOLUMES (A**3) : 0.076 REMARK 3 NON-ZERO CHIRAL VOLUMES (A**3) : 0.086 REMARK 3 ANTI-BUMPING DISTANCE RESTRAINTS (A) : 0.023 REMARK 3 RIGID-BOND ADP COMPONENTS (A**2) : 0.005 REMARK 3 SIMILAR ADP COMPONENTS (A**2) : 0.050 REMARK 3 APPROXIMATELY ISOTROPIC ADPS (A**2) : 0.098 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED: MOEWS & KRETSINGER, J.MOL.BIOL.91(1973)201-228 REMARK 3 REMARK 3 STEREOCHEMISTRY TARGET VALUES : ENGH & HUBER REMARK 3 SPECIAL CASE: NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: REFINEMENT IN X-PLOR, ALTERNATED REMARK 3 WITH MANUAL REBUILDING IN O, RESULTING IN A FREE R-FACTOR REMARK 3 OF 24.0%. SRI-9439 WAS THEN ADDED TO THE MODEL IN THE REMARK 3 ACTIVE SITE AND THE CIS PEPTIDE BONDS BETWEEN RESIDUES REMARK 3 ARG-65 AND PRO-66 AND RESIDUES GLY-116 AND GLY-117 BECAME REMARK 3 APPARENT IN 2FO-FC AND FO-FC MAPS. REFINEMENT PROCEEDED REMARK 3 WITH THE ADDITION OF RIDING HYDROGEN ATOMS AND ANISOTROPIC REMARK 3 TEMPERATURE FACTORS IN REFMAC AND ARP, YIELDING A FREE REMARK 3 R-FACTOR OF 19.4%. AT THIS POINT, MOST OF THE SIDE CHAIN REMARK 3 ALTERNATE CONFORMATIONS WERE MODELED. ANISOTROPIC REMARK 3 DISPLACEMENT PARAMETERS WERE REFINED IN SHELXL AND RIDING REMARK 3 HYDROGEN ATOMS WERE ADDED. IN THE FINAL ROUNDS OF REMARK 3 REFINEMENT, RESTRAINTS FOR ALL ATOMS IN SRI-9439 REMARK 3 EXCEPT FOR REMARK 3 PLANARITY RESTRAINTS ON THE 5-QUINOLYLAMINO GROUP, AND ALL REMARK 3 NADPH ATOMS EXCEPT FOR THOSE IN THE ADENINE RING AND ADENINE REMARK 3 RIBOSE-2-PHOSPHATE WERE REMOVED, GIVING THE FINAL FREE R-FACTOR REMARK 3 (17.3%). ATTEMPTS TO RESTRAIN THE PLANARITY OF THE REMARK 3 5-METHYL-5-DEAZAPTERIDINE MOIETY OF SRI-9439 RESULTED REMARK 3 IN LARGE DIFFERENCE ELECTRON DENSITY PEAKS FOR THE REMARK 3 EXOCYCLIC N4 AND C5A ATOMS, CONFIRMING THEIR OUT-OF-PLANE REMARK 3 POSITIONS. REMARK 4 REMARK 4 1KMS COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 07-JAN-02. REMARK 100 THE DEPOSITION ID IS D_1000015119. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 25-JUN-97 REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 8.00 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SSRL REMARK 200 BEAMLINE : BL7-1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.08 REMARK 200 MONOCHROMATOR : SI (111) REMARK 200 OPTICS : PT-COATED MIRROR REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : MARRESEARCH REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : CCP4 (SCALA) REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 79611 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.090 REMARK 200 RESOLUTION RANGE LOW (A) : 20.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.6 REMARK 200 DATA REDUNDANCY : 3.600 REMARK 200 R MERGE (I) : 0.04700 REMARK 200 R SYM (I) : 0.04700 REMARK 200 FOR THE DATA SET : 9.4000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.09 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.15 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.1 REMARK 200 DATA REDUNDANCY IN SHELL : 3.30 REMARK 200 R MERGE FOR SHELL (I) : 0.42200 REMARK 200 R SYM FOR SHELL (I) : 0.42200 REMARK 200 FOR SHELL : 2.300 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: UNPUBLISHED HUMAN DHFR STRUCTURE. REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 46.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.23 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: THE TERNARY COMPLEX OF DHFR WITH NADPH REMARK 280 AND SRI-9439 WAS FORMED BY MIXING HUMAN DHFR (20 MG/ML IN 25 MM REMARK 280 KPO4 (PH 7.0), 0.1 MM EDTA, AND 3 MM NAN3) WITH 60 MM NADPH, REMARK 280 FOLLOWED 15 MINUTES LATER BY 60 MM OF INHIBITOR IN DMSO (FINAL REMARK 280 CONCENTRATIONS OF 2 MM NADPH AND 2 MM INHIBITOR). THIS COMPLEX REMARK 280 SOLUTION WAS MIXED WITH AN EQUAL VOLUME OF PRECIPITANT REMARK 280 CONTAINING 24-33% PEG 4000, 0.2 M LI2SO4, 0.1 M TRIS CL (PH 7.9- REMARK 280 8.4), AND EQUILIBRATED WITH THE PRECIPITANT BY HANGING DROP REMARK 280 VAPOR DIFFUSION AT 277 K. THE CRYSTAL GREW IN ABOUT 3 WEEKS. THE REMARK 280 CRYSTAL WAS FLASH-COOLED DIRECTLY IN LIQUID NITROGEN AFTER REMARK 280 HARVESTING INTO MOTHER LIQUOR CONTAINING 10% GLYCEROL., PH 8.00, REMARK 280 VAPOR DIFFUSION, HANGING DROP REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 20.73350 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 41.39950 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 27.63750 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 41.39950 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 20.73350 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 27.63750 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 VAL A 1 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLY A 2 N CA O REMARK 470 GLU A 101 CD OE1 OE2 REMARK 470 GLN A 102 NE2 REMARK 470 GLU A 143 CD OE1 OE2 REMARK 470 LYS A 173 NZ REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 LEU A 4 CA - CB - CG ANGL. DEV. = 15.4 DEGREES REMARK 500 ASP A 21 CB - CG - OD1 ANGL. DEV. = 5.4 DEGREES REMARK 500 PHE A 31 CB - CG - CD2 ANGL. DEV. = 4.6 DEGREES REMARK 500 ARG A 32 NE - CZ - NH1 ANGL. DEV. = 3.4 DEGREES REMARK 500 ARG A 32 NE - CZ - NH2 ANGL. DEV. = -4.1 DEGREES REMARK 500 MET A 37 CG - SD - CE ANGL. DEV. = -9.8 DEGREES REMARK 500 ARG A 65 NE - CZ - NH1 ANGL. DEV. = 3.5 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 110 -92.78 -102.11 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 203 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 204 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE LIH A 201 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE NDP A 202 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1KMV RELATED DB: PDB REMARK 900 HUMAN DIHYDROFOLATE REDUCTASE COMPLEXED WITH NADPH AND (Z)-6-(2-[2, REMARK 900 5-DIMETHOXYPHENYL]ETHEN-1-YL)-2,4-DIAMINO-5-METHYLPYRIDO[2,3-D] REMARK 900 PYRIMIDINE (SRI-9662), A LIPOPHILIC ANTIFOLATE DBREF 1KMS A 1 186 UNP P00374 DYR_HUMAN 1 186 SEQRES 1 A 186 VAL GLY SER LEU ASN CYS ILE VAL ALA VAL SER GLN ASN SEQRES 2 A 186 MET GLY ILE GLY LYS ASN GLY ASP LEU PRO TRP PRO PRO SEQRES 3 A 186 LEU ARG ASN GLU PHE ARG TYR PHE GLN ARG MET THR THR SEQRES 4 A 186 THR SER SER VAL GLU GLY LYS GLN ASN LEU VAL ILE MET SEQRES 5 A 186 GLY LYS LYS THR TRP PHE SER ILE PRO GLU LYS ASN ARG SEQRES 6 A 186 PRO LEU LYS GLY ARG ILE ASN LEU VAL LEU SER ARG GLU SEQRES 7 A 186 LEU LYS GLU PRO PRO GLN GLY ALA HIS PHE LEU SER ARG SEQRES 8 A 186 SER LEU ASP ASP ALA LEU LYS LEU THR GLU GLN PRO GLU SEQRES 9 A 186 LEU ALA ASN LYS VAL ASP MET VAL TRP ILE VAL GLY GLY SEQRES 10 A 186 SER SER VAL TYR LYS GLU ALA MET ASN HIS PRO GLY HIS SEQRES 11 A 186 LEU LYS LEU PHE VAL THR ARG ILE MET GLN ASP PHE GLU SEQRES 12 A 186 SER ASP THR PHE PHE PRO GLU ILE ASP LEU GLU LYS TYR SEQRES 13 A 186 LYS LEU LEU PRO GLU TYR PRO GLY VAL LEU SER ASP VAL SEQRES 14 A 186 GLN GLU GLU LYS GLY ILE LYS TYR LYS PHE GLU VAL TYR SEQRES 15 A 186 GLU LYS ASN ASP HET SO4 A 203 5 HET SO4 A 204 5 HET LIH A 201 25 HET NDP A 202 48 HETNAM SO4 SULFATE ION HETNAM LIH 6-([5-QUINOLYLAMINO]METHYL)-2,4-DIAMINO-5- HETNAM 2 LIH METHYLPYRIDO[2,3-D]PYRIMIDINE HETNAM NDP NADPH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE HETNAM 2 NDP PHOSPHATE HETSYN LIH SRI-9439 FORMUL 2 SO4 2(O4 S 2-) FORMUL 4 LIH C18 H17 N7 FORMUL 5 NDP C21 H30 N7 O17 P3 FORMUL 6 HOH *399(H2 O) HELIX 1 1 LEU A 27 THR A 40 1 14 HELIX 2 2 LYS A 54 ILE A 60 1 7 HELIX 3 3 PRO A 61 ARG A 65 5 5 HELIX 4 4 SER A 92 GLU A 101 1 10 HELIX 5 5 GLY A 117 ASN A 126 1 10 SHEET 1 A 8 PHE A 88 SER A 90 0 SHEET 2 A 8 ILE A 71 LEU A 75 1 N VAL A 74 O PHE A 88 SHEET 3 A 8 GLN A 47 GLY A 53 1 N VAL A 50 O ILE A 71 SHEET 4 A 8 VAL A 109 ILE A 114 1 O TRP A 113 N LEU A 49 SHEET 5 A 8 LEU A 4 VAL A 10 1 N ASN A 5 O ILE A 114 SHEET 6 A 8 LEU A 131 ILE A 138 1 O PHE A 134 N CYS A 6 SHEET 7 A 8 ILE A 175 LYS A 184 -1 O LYS A 178 N ARG A 137 SHEET 8 A 8 TYR A 156 LEU A 158 -1 N LYS A 157 O GLU A 183 SHEET 1 B 8 PHE A 88 SER A 90 0 SHEET 2 B 8 ILE A 71 LEU A 75 1 N VAL A 74 O PHE A 88 SHEET 3 B 8 GLN A 47 GLY A 53 1 N VAL A 50 O ILE A 71 SHEET 4 B 8 VAL A 109 ILE A 114 1 O TRP A 113 N LEU A 49 SHEET 5 B 8 LEU A 4 VAL A 10 1 N ASN A 5 O ILE A 114 SHEET 6 B 8 LEU A 131 ILE A 138 1 O PHE A 134 N CYS A 6 SHEET 7 B 8 ILE A 175 LYS A 184 -1 O LYS A 178 N ARG A 137 SHEET 8 B 8 GLN A 170 GLU A 172 -1 N GLN A 170 O TYR A 177 SHEET 1 C 2 GLY A 15 GLY A 17 0 SHEET 2 C 2 THR A 146 PHE A 147 -1 O THR A 146 N GLY A 17 CISPEP 1 ARG A 65 PRO A 66 0 -5.49 CISPEP 2 GLY A 116 GLY A 117 0 4.45 SITE 1 AC1 4 PRO A 61 GLU A 62 HOH A 500 HOH A 524 SITE 1 AC2 7 ARG A 28 LYS A 68 GLY A 69 HOH A 375 SITE 2 AC2 7 HOH A 608 HOH A 658 HOH A 695 SITE 1 AC3 12 ILE A 7 VAL A 8 GLU A 30 PHE A 31 SITE 2 AC3 12 PHE A 34 PRO A 61 VAL A 115 TYR A 121 SITE 3 AC3 12 NDP A 202 HOH A 302 HOH A 343 HOH A 401 SITE 1 AC4 38 VAL A 8 ALA A 9 ILE A 16 GLY A 17 SITE 2 AC4 38 LYS A 18 GLY A 20 ASP A 21 LEU A 22 SITE 3 AC4 38 TRP A 24 GLY A 53 LYS A 54 LYS A 55 SITE 4 AC4 38 THR A 56 LEU A 75 SER A 76 ARG A 77 SITE 5 AC4 38 GLU A 78 ARG A 91 LYS A 98 VAL A 115 SITE 6 AC4 38 GLY A 117 SER A 118 SER A 119 VAL A 120 SITE 7 AC4 38 TYR A 121 GLU A 123 THR A 146 LIH A 201 SITE 8 AC4 38 HOH A 317 HOH A 339 HOH A 389 HOH A 400 SITE 9 AC4 38 HOH A 401 HOH A 435 HOH A 581 HOH A 584 SITE 10 AC4 38 HOH A 643 HOH A 689 CRYST1 41.467 55.275 82.799 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.024116 0.000000 0.000000 0.00000 SCALE2 0.000000 0.018091 0.000000 0.00000 SCALE3 0.000000 0.000000 0.012077 0.00000